alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Order entered July 13 , 2015

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05

- 15

- 00365

- CR

MARK ANGELO GUAJARDO , Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 291st Judicial District Court

Dallas County, Texas Trial Co urt Cause No. F13

- 72357

- U



### O RDER

The Court ORDERS the trial court to make findings of fact regarding whether appellant

has been deprived of the reporter’s record because of ineffective counsel, indigence, or for any

other reason.

 The trial court shall fir st determine whether appellant desires to prosecute the appeal. If the trial court determines that appellant does not desire to prosecute the appeal, it shall make a finding to that effect.

 If the trial court determines that appellant desires to prosecut e the appeal, it shall next determine whether appellant is indigent and entitled to proceed without payment of costs for the reporter’s record. If appellant is entitled to proceed without payment of costs, the trial court shall make a finding to that effe ct. Moreover, if appellant is indigent, the trial court is ORDERED to take such measures as may be necessary to assure effective representation, which may include appointment of new counsel. If the trial court finds appellant is not indigent, it shall de termine whether retained counsel has abandoned the appeal. The trial court shall next determine: (1) the name and address of each court reporter who

recorded the proceedings in this cause; (2) the court reporter’s explanation for the delay in filing the reporter’s record; and (3) the earliest date by which the reporter’s record can be filed.

We ORDER the trial court to transmit a record, containing the written findings of fact,

any supporting documentation, and any orders, to this Court within THIRTY DA YS of the date

of this order.

The appeal is ABATED to allow the trial court to comply with this order. The appeal

shall be reinstated thirty days from the date of this order or when the findings are received,

whichever is earlier. /s/ LANA MYERS JUSTICE
Editorial Note on Part 112
Editorial Note: Nomenclature changes to part 112 appear at 81 FR 49896, July 29, 2016.

§ 112.207 What is the procedure for requesting an informal hearing? ( a ) If the owner, operator, or agent in charge of the farm appeals the order, the owner, operator, or agent in charge of the farm: ( 1 ) May request an informal hearing; and
( 2 ) Must submit any request for an informal hearing together with its written appeal submitted in accordance with § 112.206 within 15 calendar days of the date of receipt of the order.
( b ) A request for an informal hearing may be denied, in whole or in part, if the presiding officer determines that no genuine and substantial issue of material fact has been raised by the material submitted. If the presiding officer determines that a hearing is not justified, a written notice of the determination will be given to the owner, operator, or agent in charge of the farm explaining the reason for the denial.
§ 2429.10 What does this part do? This part requires that the award and administration of HUD grants and cooperative agreements comply with Office of Management and Budget (OMB) guidance implementing the portion of the Drug-Free Workplace Act of 1988 (41 U.S.C. 701-707) (referred to as the Act in this part) that applies to grants. This part: ( a ) Gives regulatory effect to the OMB guidance (Subparts A through F of 2 CFR part 182) for HUD grants and cooperative agreements; and
( b ) Establishes HUD policies and procedures for compliance with the Act that are the same as those of other Federal agencies, in conformance with the requirement in 41 U.S.C. 705 for governmentwide implementing regulations.
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 727 Engrossed in House (EH)]

<DOC>
H. Res. 727

                In the House of Representatives, U. S.,

                                                      February 6, 2018.
    Resolved, That upon adoption of this resolution it shall be in order to take 
from the Speaker's table the bill (H.R. 1892) to amend title 4, United States 
Code, to provide for the flying of the flag at half-staff in the event of the 
death of a first responder in the line of duty, with the Senate amendment 
thereto, and to consider in the House, without intervention of any point of 
order, a motion offered by the chair of the Committee on Appropriations or his 
designee that the House concur in the Senate amendment with an amendment 
consisting of the text of Rules Committee Print 115-58 modified by the amendment 
printed in the report of the Committee on Rules accompanying this resolution. 
The Senate amendment and the motion shall be considered as read. The motion 
shall be debatable for one hour equally divided and controlled by the chair and 
ranking minority member of the Committee on Appropriations. The previous 
question shall be considered as ordered on the motion to its adoption without 
intervening motion.
            Attest:

                                                                          Clerk.
```
NICHOLAS JOSHUA GEE

,

Appellant,

v.

STATE OF FLORIDA

,

Appellee

. IN THE DISTRICT COURT OF APPEAL

FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO

FILE MOTION FOR REHEARING AND

DISPOSITION THEREOF IF FILED

CASE NO. 1D 15

- 5629

____ _________________________/

Opinion filed June 14, 2016.

An appeal from an order of the Circuit Court for Duval County

. Angela Cox , Judge

.

Nancy A. Daniels, Public Defender, and Steven L. Seliger, Assistant Public

Defender, Tallahassee , for Appellant; Ni cholas Joshua Gee, pro se, Appellant.

Pamela Jo Bondi, Attorney General, Tallahassee , for Appellee.

PER CURIAM.

AFFIRMED.

ROWE, KELSEY, and JAY, JJ., CONCUR.
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 1083 Referred in House (RFH)]

<DOC>

115th CONGRESS
  1st Session
                                S. 1083

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 16, 2017

      Referred to the Committee on Oversight and Government Reform

_______________________________________________________________________

                                 AN ACT

 
 To amend section 1214 of title 5, United States Code, to provide for 
 stays during a period that the Merit Systems Protection Board lacks a 
                                quorum.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. STAYS BY MSPB DURING PERIODS WITH NO QUORUM.

    Section 1214(b)(1)(B) of title 5, United States Code, is amended--
            (1) by inserting ``(i)'' before ``The Board may''; and
            (2) by adding at the end the following:
    ``(ii) If the Board lacks the number of members appointed under 
section 1201 required to constitute a quorum, any remaining member of 
the Board who was appointed, by and with the advice and consent of the 
Senate, shall, upon request by the Special Counsel, extend the period 
of any stay granted under subparagraph (A).''.

            Passed the Senate May 11, 2017.

            Attest:

                                                JULIE E. ADAMS,

                                                             Secretary.
```
§ 1.230 When must you register or renew your registration? ( a ) *Registration.* You must register before your facility begins to manufacture, process, pack, or hold food for consumption in the United States. You may authorize an individual to register the facility on your behalf.
( b ) *Registration renewal.* You must submit a registration renewal containing the information required under § 1.232 every other year, during the period beginning on October 1 and ending on December 31 of each even-numbered year. You may authorize an individual to renew a facility's registration on your behalf. If the individual submitting the registration renewal is not the owner, operator, or agent in charge of the facility, the registration renewal must also include a statement in which the individual certifies that the information submitted is true and accurate, certifies that he/she is authorized to submit the registration renewal, and identifies by name, address, and telephone number, the individual who authorized submission of the registration renewal. In addition, the registration renewal must also identify the individual who authorized submission of the registration renewal by email address, unless FDA has granted a waiver under § 1.245. Each registration renewal must include the name of the individual submitting the registration renewal, and the individual's signature (for the paper option). Each electronic registration renewal must include the name of the individual submitting the renewal.
( c ) *Abbreviated registration renewal process.* If you do not have any changes to the information required under § 1.232 since you submitted the preceding registration, registration renewal, or update for your facility, you may use the abbreviated registration renewal process. If you use the abbreviated registration renewal process, you must confirm that no changes have been made to the information required under § 1.232 since you submitted the preceding registration, registration renewal or update, and you must certify that the information submitted is truthful and accurate. Each abbreviated registration renewal must include the name of the individual submitting the abbreviated renewal, and the individual's signature (for the paper option). Each electronic abbreviated registration renewal must include the name of the individual submitting the abbreviated renewal. For abbreviated registration renewals not submitted by the owner, operator, or agent in charge of the facility, the abbreviated renewal must provide the email address of the individual who authorized submission of the abbreviated renewal, unless FDA has granted a waiver under § 1.245. You must use Form FDA 3537 to submit abbreviated registration renewals to FDA.
[81 FR 45950, July 14, 2016]
#### § 200.474 Transportation costs.

Costs incurred for freight, express, cartage, postage, and other transportation services relating either to goods purchased, in process, or delivered, are allowable. When such costs can readily be identified with the items involved, they may be charged directly as transportation costs or added to the cost of such items. Where identification with the materials received cannot readily be made, inbound transportation cost may be charged to the appropriate indirect (F&A) cost accounts if the non-Federal entity follows a consistent, equitable procedure in this respect. Outbound freight, if reimbursable under the terms and conditions of the Federal award, should be treated as a direct cost.

[78 FR 78608, Dec. 26, 2013. Redesignated at 85 FR 49570, Aug. 13, 2020]
JUDGMENT

Court of Appeals 

 

First District of Texas 

NO. 01-13-00897-CR

CESAR ROCHA, Appellant

V.

THE STATE OF TEXAS, Appellee

Appeal from the County Criminal Court at Law No. 1 of Harris County. (Tr. Ct. No. 

1914250).

This case is an appeal from the final judgment signed by the trial court on 

September 11, 2013. After submitting the case on the appellate record and the arguments 

properly raised by the parties, the Court holds that the trial court’s judgment contains no 

reversible error. Accordingly, the Court affirms the trial court’s judgment.

The Court orders that this decision be certified below for observance.

Judgment rendered March 12, 2015.

Panel consists of Justices Higley and Bland. Opinion delivered by Justice Bland.
§ 1.633 How will FDA monitor recognized accreditation bodies? ( a ) FDA will evaluate the performance of each recognized accreditation body to determine its compliance with the applicable requirements of this subpart. Such assessment must occur by at least 4 years after the date of recognition for a 5-year recognition period, or by no later than the mid-term point for a recognition period of less than 5 years. FDA may conduct additional assessments of a recognized accreditation body at any time.
( b ) An FDA assessment of a recognized accreditation body may include onsite assessments of a representative sample of third-party certification bodies the recognized accreditation body accredited and onsite audits of a representative sample of eligible entities certified by such third-party certification bodies under this subpart. These may be conducted at any time and, as FDA determines necessary or appropriate, may occur without the recognized accreditation body or, in the case of an audit of an eligible entity, the accredited third-party certification body present.
<PAGE>   1



Exhibit 11.0

             MAGICWORKS ENTERTAINMENT INCORPORATED AND SUBSIDIARIES
              STATEMENT REGARDING COMPUTATION OF EARNINGS PER SHARE
         FOR THE THREE AND NINE MONTHS ENDED September 30, 1997 and 1996

<TABLE>
<CAPTION>

                                                    THREE MONTHS ENDED SEPTEMBER 30,  NINE MONTHS ENDED SEPTEMBER 30,
                                                          1997            1996              1997           1996
                                                    --------------------------------  -------------------------------
<S>                                                  <C>             <C>            <C>             <C>         
     PRIMARY:

Net Income (loss)                                    $   (196,212)   $   (232,234)     $     743,212   $  1,388,726

Weighted average common shares
   outstanding                                         24,400,929      23,511,042         24,396,461     22,395,221
Impact of dilutive warrants and options                         -               -             30,003         17,559
                                                     ------------    ------------      -------------   ------------

Weighted average number of common
   stock and common stock equivalents
   for primary earnings per share                      24,400,929      23,511,042         24,427,464     22,412,780
                                                     ------------    ------------      -------------   ------------

Net income per share                                 $       (.01)   $       (.01)     $         .03   $        .06
                                                     ============    ============      =============   ============


     FULLY DILUTED:

Net Income (loss)                                    $   (196,212)   $   (232,234)     $     743,212   $  1,388,726
Interest expense, net of tax benefit, on
   convertible notes                                            -               -                  -              -

Weighted average common shares
    outstanding                                        24,400,929      23,511,042         24,396,461     22,395,221
Impact of dilutive warrants and options                         -               -             30,003         18,414
Impact of convertible notes                                     -               -                  -              -
                                                     ------------    ------------      -------------   ------------

Weighted average number of common
   stock and common stock equivalents
   for fully diluted earnings per share                24,400,929      23,511,042         24,427,464     22,413,635

Net income per share                                 $       (.01)   $       (.01)     $         .03   $        .06
                                                     ============    ============      =============   ============
</TABLE>


                                                                             


                                       18
EX-35.16


(logo) WELLS FARGO

Corporate Trust Services

MAC R1204-010
9062 Old Annapolis Road
Columbia, MD 21045

Tel: 410 884 2000
Fax: 410 715 2380

Wells Fargo Commercial Mortgage Securities, Inc.
c/o Wells Fargo Securities, LLC
375 Park Avenue 2nd floor
J0127-023
New York, New York 10152-023

RE: Annual Statement of Compliance for Wells Fargo Commercial Mortgage
    Securities, Inc., Commerical Mortgage Pass-through Certificates Series 2013-
    C12

Per the Pooling and Servicing Agreement dated as of March 1, 2013 (the
"Agreement"), the undersigned, a duly authorized officer of Wells Fargo Bank,
N.A., as Certificate Administrator ("Wells Fargo"), hereby certifies as follows
as of and for the year ending December 31, 2013 (the "Reporting Period"):

(a) A review of Wells Fargo's activities during the Reporting Period and of its
    performance under the Agreement has been made under such officer's
    supervision; and

(b) To the best of such officer's knowledge, based on such review, Wells Fargo
    has fulfilled all of its obligations under the Agreement in all material
    respects throughout the Reporting Period.

March 10, 2014


/s/ Brian Smith
BRIAN SMITH
Vice President


Wells Fargo Bank, N.A.
§ 111.210 What must the master manufacturing record include? The master manufacturing record must include: ( a ) The name of the dietary supplement to be manufactured and the strength, concentration, weight, or measure of each dietary ingredient for each batch size;
( b ) A complete list of components to be used;
( c ) An accurate statement of the weight or measure of each component to be used;
( d ) The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement;
( e ) A statement of any intentional overage amount of a dietary ingredient;
( f ) A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made;
( g ) A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label;
( h ) Written instructions, including the following: ( 1 ) Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record;
( 2 ) Procedures for sampling and a cross-reference to procedures for tests or examinations;
( 3 ) Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record. ( i ) Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component; and
( ii ) For manual operations, such specific actions must include: ( A ) One person weighing or measuring a component and another person verifying the weight or measure; and
( B ) One person adding the component and another person verifying the addition.
( 4 ) Special notations and precautions to be followed; and
( 5 ) Corrective action plans for use when a specification is not met.
<PAGE>

                                                                    EXHIBIT 31.2

     CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE
                           SARBANES-OXLEY ACT OF 2002

I, Kathleen A. Bayless, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Komag, Incorporated;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements and other financial
information included in this report fairly present, in all material respects,
the financial condition and results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a - 15(e) and 15d - 15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

b) Evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of
directors:

a) All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize, and report financial information; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.

         DATE: August 9, 2004            BY: /s/ Kathleen A. Bayless
                                                 ---------------------------

                                                 Kathleen A. Bayless
                                                 Chief Financial Officer